24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis
Sponsor: Novartis Pharmaceuticals
This PHASE3 trial investigates Psoriatic Arthritis and is currently completed. Novartis Pharmaceuticals leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 7 earlier versions
-
Jan 2019 — May 2019 [monthly]
Completed PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Albany, United States , Amsterdam, Netherlands , Austin, United States , Aventura, United States , Barcelona, Spain , Barnsley, United Kingdom , Berlin, Germany , Bologna, Italy and 61 more locations